Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Wall Street thinks this weight-loss drug stock could more than 3x over the next 12 ... Also, Viking was seen by some as a ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... In a similar vein, the market has grown ...

However, Merck announced in December 2024 it was licensing ... or for those trying to maintain weight loss achieved with an injection. Unlike many clinical-stage biotech companies, though, Viking ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

For example, the Swiss business Roche entered the weight-loss drug sweepstakes in 2023 when ... 208 percentage points (see more details here). Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...